0000850261 false 0000850261 2023-10-25 2023-10-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, D.C. 20549










Date of Report (Date of earliest event reported): October 25, 2023




(Exact Name of Registrant as Specified in its Charter)



Delaware   001-36150   33-0344842

(State or Other Jurisdiction

of Incorporation)



File Number)


(IRS Employer

Identification No.)


4955 Directors Place

San Diego, CA 92121

(Address of Principal Executive Offices) (Zip Code)


Registrant’s telephone number, including area code: (858) 203-4100



(Former Name, or Former Address, if Changed Since Last Report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities Registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, $0.0001 par value   SRNE   The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨







Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On October 25, 2023, Tammy Reilly notified Sorrento Therapeutics, Inc. (the “Company”) that she was resigning from the Board of Directors of the Company (the “Board”), effective immediately. Ms. Reilly informed the Company that her resignation was due to concerns regarding the Company’s Chief Restructuring Officer’s continued lack of communication with the Board on decisions made and the general operating of the Company and changes in the Company’s directors’ and officers’ insurance policy without Board input. A copy of Ms. Reilly’s letter of resignation is attached hereto as Exhibit 17.1.


The Company has provided Ms. Reilly with a copy of the disclosures in this Form 8-K and the opportunity to furnish the Company with a letter addressed to the Company stating whether she agrees with the statements made by the Company in response to this Item 5.02 and if not, stating the respects in which she does not agree. Upon the receipt of any such letter from Ms. Reilly, the Company will file any such letter as an exhibit to an amendment to this Form 8-K, no later than two business days after it is received.


Item 9.01. Financial Statements and Exhibits.


(d) Exhibits.


17.1 Ms. Reilly Resignation Letter, dated October 25, 2023.
104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



Date: October 27, 2023 By: /s/ Henry Ji, Ph.D.  
    Name: Henry Ji, Ph.D.  
    Title: Chief Executive Officer  







Exhibit 17.1


From: Tammy Reilly <[…***…]@[…***…].com>

Sent: Wednesday, October 25, 2023 11:46 AM

To: Henry Ji <[…***…]@sorrentotherapeutics.com>

Subject: BOD Resignation


Good morning,


It is with dismay that I inform you of my decision to resign from the Board of Directors for Sorrento Therapeutics effective immediately.


I have become increasingly concerned at the CRO’s continued lack of communication with the BOD on decisions made and general operating of the company thus, resulting in unilateral decision making by the CRO. Further to this, the decision by the CRO without BOD input to ineffectively and irresponsibility act regarding changes in the D&O policy reinforced my decision.




Tammy Reilly